The European Investment Bank (EIB) has announced a €100 million loan to Univercells, a Belgian biotechnology company, to support the expansion of its biomanufacturing facilities in Jumet, Belgium. This investment aims to enhance the production capacity for vaccines and biologics, addressing growing global demand for accessible and affordable biotherapeutics.

The funding will enable Univercells to scale up its manufacturing infrastructure, focusing on innovative and cost-effective production technologies. The expansion is expected to create new jobs and strengthen Belgium's position as a key hub for life sciences and pharmaceutical manufacturing in Europe.

This initiative aligns with the European Union's broader strategy to bolster regional health security and ensure a resilient supply chain for critical medical products. For more details, visit the EIB official announcement.